for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Decibel Therapeutics Inc

DBTX.OQ

Latest Trade

10.54USD

Change

-0.08(-0.75%)

Volume

13,576

Today's Range

10.49

 - 

10.94

52 Week Range

10.44

 - 

24.35

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
10.62
Open
10.68
Volume
13,576
3M AVG Volume
--
Today's High
10.94
Today's Low
10.49
52 Week High
24.35
52 Week Low
10.44
Shares Out (MIL)
24.90
Market Cap (MIL)
264.45
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Orbimed Advisors Reports 16.7% Stake In Decibel Therapeutics As Of Feb 17

Decibel Therapeutics Shares Open 17.8% Above IPO Price In Nasdaq Debut

Decibel Therapeutics Announces Pricing Of IPO

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Decibel Therapeutics Inc

Decibel Therapeutics Inc is a clinical-stage biotechnology company. The Company is focused on discovering and developing transformative treatments for hearing and balance disorders. The Company is focused on restoring and improving hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the inner ear. The Company has built a platform that integrates single-cell genomics and bioinformatics analyses, precision gene therapy technologies and its proficiency in inner ear biology. The Company’s pipeline product includes its gene therapy program (DB-OTO) to treat congenital monogenic deafness and its ototoxicity prevention program. Its products pipeline also includes AAV.103, AAV.104, DB-ATO and AAV.201.

Industry

Business Services

Contact Info

1325 Boylston Street, Suite 500

BOSTON, MA

02215

United States

+1.617.3708701

https://www.decibeltx.com/

Executive Leadership

Laurence E. Reid

Chief Executive Officer, Director

Gabriel Corfas

Founder

M. Charles Liberman

Founder

Ulrich Mueller

Founder

Elisabeth Leiderman

Chief Financial Officer, Head of Corporate Development

Key Stats

1.50 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2021(E)

0.0K
EPS (USD)

2021(E)

-1.722
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up